Research use onlyFor laboratory and research purposes only — not for human consumption, medical, veterinary or diagnostic use.

PeptideStacks
Recovery & Performance

Ipamorelin + CJC-1295 + BPC-157 Recomposition Stack

GHRH/GHRP pulse stack combined with BPC-157 connective-tissue support — research protocol for body recomposition models.

3 peptides 12-week cycle intermediate
GH pulse amplificationIGF-1 elevationConnective tissue supportBody composition research

The Ipamorelin + CJC-1295 (no DAC) + BPC-157 stack is a three-peptide research protocol designed around two distinct pharmacological strategies that operate in parallel. The first strategy — the GHRH/GHRP pulse pair — amplifies endogenous GH secretion at the pituitary level without suppressing the hypothalamic-pituitary axis or disturbing cortisol and prolactin secretion. The second strategy deploys BPC-157's connective-tissue repair signal to protect tendons, ligaments and muscle fascia from the increased mechanical load that accompanies heightened GH-axis activity in research settings. All three compounds are unapproved research peptides. This page summarises the published in vitro, animal-model and early clinical Phase I findings on each peptide and the rationale for their combination.

Why three peptides for body recomposition research?

Body recomposition — simultaneous reduction in fat mass and preservation or accretion of lean tissue — depends on elevated GH pulse amplitude, elevated IGF-1 and adequate connective-tissue integrity to tolerate the load placed on tendons and ligaments during high-output activity. No single peptide addresses all three variables efficiently.

CJC-1295 (no DAC), a stabilised analogue of GHRH(1-29) refined in the laboratory context by researchers including Jens Sandahl Christiansen and Henrik Nielsen, acts at GHRH receptors on pituitary somatotropes to increase the amplitude of each GH pulse. Ipamorelin, discovered by J Raun and colleagues at Novo Nordisk in the late 1990s, is a GHRP-class secretagogue that triggers the GH pulse at the somatotrope via the ghrelin receptor. When administered simultaneously, GHRH-receptor and ghrelin-receptor activation are synergistic — the combined GH pulse area-under-the-curve substantially exceeds the sum of either peptide alone. BPC-157, characterised extensively by Predrag Sikiric and his Zagreb group, closes the third gap: its documented promotion of tendon outgrowth, collagen organisation and angiogenesis in rodent models provides connective-tissue support during the period of elevated GH/IGF-1 signalling.

Mechanism of action — each peptide

Ipamorelin — mechanism of action

Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide growth hormone secretagogue characterised in a landmark 1998 Phase I study by Raun et al. (PMID 9849822). It acts as a selective agonist at the ghrelin receptor (GHS-R1a) on anterior pituitary somatotropes, triggering discrete GH pulses without the off-target hormonal perturbation associated with earlier GHRPs:

  • Selectivity for GH over cortisol and prolactin — the key pharmacological distinction documented by Raun and Johansen. At doses producing maximal GH release, Ipamorelin does not significantly elevate ACTH, cortisol, aldosterone or prolactin in rodent models, making it suitable for multi-week research protocols.
  • Pulse-pattern preservation — because Ipamorelin acts at the secretagogue receptor without suppressing somatostatin tone, the physiological pulsatile pattern of GH secretion is largely maintained rather than converted to a sustained plateau.
  • Short half-life (~2 hours) — plasma clearance is rapid, which means GH elevation is tightly linked to injection timing. This property is exploited by the three-times-daily research dosing schedule to create three discrete daily pulses aligned with fasting, sleep-onset and post-exercise windows.
  • Synergy with GHRH — at the somatotrope, ghrelin-receptor and GHRH-receptor activation share downstream cAMP and PKC signalling pathways that are additive when co-stimulated. This is the mechanistic basis for the Ipamorelin + CJC-1295 combination.

CJC-1295 (no DAC) — mechanism of action

CJC-1295 without DAC (also designated Mod GRF 1-29) is a 29-amino-acid synthetic analogue of GHRH(1-29) with four amino acid substitutions that improve protease resistance and receptor affinity relative to native GHRH. Its pharmacology was characterised in human Phase I studies by Teichman et al. (PMID 16352683) and the receptor pharmacokinetics examined by Jetté et al. (PMID 15802499):

  • Half-life of approximately 30 minutes (in the absence of the DAC modification) — producing a GH pulse window that corresponds closely to physiological GHRH secretory bursts from the hypothalamus.
  • Dose-dependent IGF-1 elevation — Teichman et al. documented mean IGF-1 increases of 30–50% above baseline in healthy adults after single CJC-1295 doses of 30–60 µg/kg, with elevations detectable for 6 days. In multi-dose protocols, IGF-1 was sustained significantly above baseline throughout the dosing period without evidence of tachyphylaxis over the study duration.
  • Pituitary selectivity — like native GHRH, CJC-1295 no DAC stimulates GH release through adenylate cyclase activation at the somatotrope. It does not directly stimulate adrenal, thyroid or gonadal hormone release.
  • Synergy with GHRPs — co-administration with a ghrelin-receptor agonist (Ipamorelin) produces a GH pulse approximately 3–6 times larger than either peptide alone in rodent models, reflecting the convergent amplification of the somatotrope's secretory response when both receptor populations are simultaneously engaged.

BPC-157 — mechanism of action

BPC-157 (Body Protection Compound 157) is a stable 15-amino-acid pentadecapeptide sequence derived from human gastric juice protein, studied extensively by Predrag Sikiric and the Zagreb group over three decades. Its role in this stack is connective-tissue protection during the period of elevated GH/IGF-1 signalling:

  • Promotion of tendon outgrowth and cell migration — Chang et al. (PMID 21030672) demonstrated that BPC-157 significantly accelerated tendon fibroblast outgrowth from explant cultures, enhanced cell survival under serum-deprivation stress, and promoted directed cell migration in a scratch-wound assay. These findings directly support BPC-157's role as a tendon-protective adjunct during high-load phases.
  • Muscle repair under glucocorticoid impairment — Pevec et al. (PMID 20190678) showed that BPC-157 partially reversed the impairment in muscle healing produced by systemic corticosteroid administration in rodents, demonstrating protective effects at the level of skeletal muscle fibre repair.
  • VEGFR2-mediated angiogenesis — BPC-157 up-regulates vascular endothelial growth factor receptor 2 expression, accelerating capillary sprouting into hypoxic repair zones within 24–72 hours of administration.
  • NO-system modulation — documented by Sikiric et al. (PMID 21548867, PMID 20166987), BPC-157 normalises nitric oxide signalling in both excess-NO and deficiency states, providing a cytoprotective buffer that is relevant at both tendon and GI-tract level.
  • Short plasma half-life — the rationale for twice-daily subcutaneous research dosing; tissue-level signals persist longer than plasma levels would predict due to local receptor engagement.

Summarised studies on the combination

No single published study has investigated the Ipamorelin + CJC-1295 + BPC-157 triple combination as a defined protocol. However, the scientific basis for the combination rests on a convergent body of evidence across three well-characterised areas.

GHRH + GHRP synergy (Phase I human data): The Teichman et al. Phase I study (PMID 16352683) established that CJC-1295 without DAC produces robust, dose-dependent IGF-1 elevations in healthy adults — mean increases of 30–50% at the 30 µg/kg dose level, sustained across multi-day dosing windows without axis suppression. The synergy between GHRH-class peptides and GHRP-class peptides is further supported by Alba et al. (PMID 16046455), who demonstrated in GH-releasing hormone knockout mice that GHRP-2 (pharmacologically comparable to Ipamorelin at the secretagogue receptor) partially restored GH pulsatility, confirming that GHRP action at the pituitary is partly independent of hypothalamic GHRH. The combination therefore restores or amplifies both limbs of the GH secretory axis simultaneously.

Ipamorelin selectivity (reducing confounders): Raun et al. (PMID 9849822) established that Ipamorelin's selectivity profile — GH release without cortisol, prolactin or ACTH elevation — is superior to GHRP-2 and hexarelin for sustained research protocols. This selectivity is critical in a 12-week protocol: cortisol elevation would suppress collagen synthesis and counteract BPC-157's tissue-repair signal, so Ipamorelin's clean GH/IGF-1 axis engagement is not merely a safety consideration but a mechanistic design choice.

BPC-157 tendon and muscle protection (rodent models): Chang et al. (PMID 21030672) documented a 2.3-fold increase in tendon fibroblast outgrowth at 10 ng/mL BPC-157 versus vehicle control. Pevec et al. (PMID 20190678) showed significant recovery of muscle-repair indices in corticosteroid-impaired rodents. Sikiric et al. (PMID 21548867) reviewed the cumulative gastric, tendon, ligament and vascular findings and identified the NO system as the common mediator — a mechanistically distinct pathway from the GH axis, providing additive rather than redundant protection.

The combination has not been tested in any registered human clinical trial. All evidence for the triple stack is extrapolated from separate Phase I (GHRH/GHRP) and preclinical (BPC-157) datasets.

Full research protocol

The protocol below mirrors the dosing ranges documented across the published literature and summarised in the frontmatter of this page.

PeptideDoseFrequencyTimingCycle length
Ipamorelin200–300 µg3x daily SCPre-fasted, pre-bed, post-workout8–12 weeks
CJC-1295 (no DAC)100 µg3x daily SC co-administeredWith Ipamorelin8–12 weeks
BPC-157500 µgTwice daily SCAM + PM8–12 weeks

Weekly research timeline

PeptideWk 1Wk 2Wk 3Wk 4Wk 5Wk 6Wk 7Wk 8Wk 9Wk 10Wk 11Wk 12
Ipamorelin200 µg 3x300 µg 3x300 µg 3x300 µg 3x————————
CJC-1295 (no DAC)100 µg 3x100 µg 3x100 µg 3x100 µg 3x————————
BPC-157500 µg BID500 µg BID500 µg BID500 µg BID————————
  • Induction phase (weeks 1–2): Ipamorelin begins at the lower 200 µg per injection to establish tolerance; CJC-1295 no DAC and BPC-157 are started at full research dose from day one. The first two weeks establish the GH-pulse pattern and initiates BPC-157's early angiogenic signal in connective tissue.
  • Full-dose phase (weeks 3–10): All three peptides run at their full research doses. IGF-1 elevation typically stabilises within this window based on the Teichman Phase I data. BPC-157's twice-daily schedule maintains continuous tissue-level receptor engagement throughout.
  • Consolidation phase (weeks 11–12): All three peptides continue at the same doses; this phase allows IGF-1 to sustain elevated levels while BPC-157 completes its connective-tissue remodelling signal. No taper is required for either GHRH/GHRP agents based on published protocols.
  • Post-cycle observation (weeks 13–16): IGF-1 typically normalises within 2–4 weeks of cessation based on the Phase I half-life data. A 4-week wash-out is standard before any repeat research cycle.

Reconstitution & storage notes

All three peptides reconstitute in bacteriostatic water. Ipamorelin and CJC-1295 no DAC are typically prepared at 2 mg/mL — at this concentration, 200 µg corresponds to 0.1 mL and 100 µg to 0.05 mL per injection, respectively. Because Ipamorelin and CJC-1295 are co-administered at the same injection time, many research protocols reconstitute them in the same vial at a combined concentration (e.g. 2 mg/mL Ipamorelin + 1 mg/mL CJC-1295 no DAC) to reduce injection count. BPC-157 is reconstituted separately at 1 mg/mL; 500 µg is drawn as 0.5 mL. All solutions should be stored at 2–8 °C and used within 30 days of reconstitution. Repeated freeze-thaw cycles degrade peptide integrity; aliquot into single-week volumes before freezing for longer storage.

Where to source these research peptides

Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.

If you are exploring this combination, you may also be interested in the CJC-1295 + Ipamorelin + Tesamorelin GH Stack, which adds Tesamorelin's visceral-adipose-selective GH-axis signal to the base GHRH/GHRP pair, the BPC-157 + TB-500 Healing Stack for a connective-tissue-focused protocol without the GH-axis component, or the TB-500 + BPC-157 Tendon Repair Stack for a tendon-injury-specific research design.

Frequently asked research questions

GH-axis activation can increase connective-tissue strain in research subjects with intense activity. BPC-157's tissue-repair signal serves as a protective adjunct in published rodent studies.

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

  1. Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5) :552-61 doi:10.1530/eje.0.1390552 · PMID: 9849822
  2. Johansen PB, Segev Y, Landau D, Phillip M, Lupu M. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Experimental Diabesity Research. 2003;4(2) :73-81 doi:10.1155/EDR.2003.73 · PMID: 14630569
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3) :799-805 doi:10.1210/jc.2005-1536 · PMID: 16352683
  4. Jetté L, Léger R, Thibaudeau K, et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005;146(7) :3052-8 doi:10.1210/en.2004-1542 · PMID: 15802499
  5. Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16) :1612-32 doi:10.2174/138161211796196954 · PMID: 21548867
  6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3) :774-80 doi:10.1152/japplphysiol.00945.2010 · PMID: 21030672
  7. Pevec D, Novinscak T, Brcic L, et al.. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor. 2010;16(3) :BR81-8 · PMID: 20190678
  8. Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism. 2005;289(6) :E762-7 doi:10.1152/ajpendo.00093.2005 · PMID: 16046455
  9. Sikiric P, Seiwerth S, Brcic L, et al.. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2010;16(10) :1224-34 doi:10.2174/138161210790945977 · PMID: 20166987

Related recovery & performance stacks

Recovery & Performanceintermediate

BPC-157 + TB-500 + GHK-Cu Advanced Recovery Protocol

Three-peptide advanced soft tissue + dermal remodelling research stack. Adds GHK-Cu copper peptide to the canonical BPC-157/TB-500 base for collagen-I:III ratio improvement.

3 peptides 8 wk cycle